Koki Shishido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Koki Shishido has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Shigeru Saito
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
19 shared publications- Tomoki Ochiai
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
12 shared publications Yutaka Tanaka
12 shared publicationsKazuki Tobita
Shonan Kamakura Gen Hosp, Dept Cardiol, Kamakura, Kanagawa, Japan
11 shared publicationsShingo Mizuno
Shonan Kamakura Gen Hosp, Dept Cardiol, Kamakura, Kanagawa, Japan
11 shared publications- Futoshi Yamanaka
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
10 shared publications
Latest Publications
- 15 March 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 86 (3) , 272-279
Safety and effectiveness of self-expanding TAVR in Japanese dialysis patients with severe aortic stenosis: 1-year outcomes
- 15 March 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 86 (3) , 272-279
Safety and effectiveness of self-expanding TAVR in Japanese dialysis patients with severe aortic stenosis: 1-year outcomes
- 1 August 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (8) , E627-E632
Distal Transradial Access For Cardiac Catheterization in Patients Undergoing Hemodialysis
Although a distal radial artery (DRA) approach has recently been used in patients undergoing cardiac catheterization, no studies have so far investigated the safety and feasibility of DRA in patients undergoing hemodialysis (HD). We aimed to investigate the incidence of conventional radial artery (CRA) occlusion and puncture site complications after DRA puncture in patients undergoing HD. Original Contribution from Journal of Invasive Cardiology. coronary intervention distal radial artery approach angiography conventional radial artery
- 1 August 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (8) , E627-E632
Distal Transradial Access For Cardiac Catheterization in Patients Undergoing Hemodialysis
Although a distal radial artery (DRA) approach has recently been used in patients undergoing cardiac catheterization, no studies have so far investigated the safety and feasibility of DRA in patients undergoing hemodialysis (HD). We aimed to investigate the incidence of conventional radial artery (CRA) occlusion and puncture site complications after DRA puncture in patients undergoing HD. Original Contribution from Journal of Invasive Cardiology. coronary intervention distal radial artery approach angiography conventional radial artery
- Open Access
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Long-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Open AccessLong-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.
- 10 January 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 214, 47-54
Sodium-Glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome With Diabetes Mellitus
- 10 January 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 214, 47-54
Sodium-Glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome With Diabetes Mellitus
- Open Access
Sodium-glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome with Diabetes Mellitus
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in cardiology and are effective in treating acute coronary syndrome (ACS). Their effects on unstable plaque in ACS patients remains unclear. This study aimed to examine the effectiveness of SGLT2i in coronary plaque phenotypes based on optical coherence tomography (OCT) images and the prognosis of ACS with type 2 diabetes mellitus (T2DM). Methods This retrospective study included 109 patients in the total cohort and 29 patients in the OCT cohort. Based on SGLT2i administration after ACS, the total cohort was categorized into non-SGLT2i (n = 69) and SGLT2i (n = 40) groups. The OCT cohort had 15 and 14 patients in non-SGLT2i and SGLT2i groups, respectively. OCT images of unstable plaque were analyzed in non-stented lesions during ACS catheterization and at 6-month follow-ups. The total cohort was assessed after 1 year for major adverse cardiovascular events (MACE), including all-cause mortality, revascularization, cerebrovascular disease, and heart failure hospitalization. Results SGLT2i improved unstable lesions with a significantly thicker fibrous cap (48 ± 15 μm vs. 26 ± 24 μm, p = 0.005), reduced lipid arc (-29 ± 12° vs. -18 ± 14°, p = 0.028), and higher % decrease in total lipid arc (-35 ± 13% vs. -19 ± 18%, p = 0.01) as well as a lower MACE incidence (Log rank p = 0.023, HR 4.72 [1.08, 20.63]) and revascularization rate (adjusted HR 6.77 [1.08, 42.52]) compared to the non-SGLT2i group. Conclusions SGLT2i stabilizes atherosclerosis and improves ACS prognosis in patients with T2DM. What is new? We analyzed serial OCT images both baseline and follow-up in patients with ACS and T2DM undergoing PCI, and evaluated how effect SGLT2i had on unstable plaques. ACS patients with SGLT2i administration showed coronary atherosclerotic lesions to be stabilized on follow-up. What are the clinical implications? SGLT2i can stabilize unstable plaques by controlling the inflammatory cascade on patients with T2DM. SGLT2i administration will be one option to improve their prognosis in patients with ACS and T2DM undergoing PCI.
Open AccessSodium-glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome with Diabetes Mellitus
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in cardiology and are effective in treating acute coronary syndrome (ACS). Their effects on unstable plaque in ACS patients remains unclear. This study aimed to examine the effectiveness of SGLT2i in coronary plaque phenotypes based on optical coherence tomography (OCT) images and the prognosis of ACS with type 2 diabetes mellitus (T2DM). Methods This retrospective study included 109 patients in the total cohort and 29 patients in the OCT cohort. Based on SGLT2i administration after ACS, the total cohort was categorized into non-SGLT2i (n = 69) and SGLT2i (n = 40) groups. The OCT cohort had 15 and 14 patients in non-SGLT2i and SGLT2i groups, respectively. OCT images of unstable plaque were analyzed in non-stented lesions during ACS catheterization and at 6-month follow-ups. The total cohort was assessed after 1 year for major adverse cardiovascular events (MACE), including all-cause mortality, revascularization, cerebrovascular disease, and heart failure hospitalization. Results SGLT2i improved unstable lesions with a significantly thicker fibrous cap (48 ± 15 μm vs. 26 ± 24 μm, p = 0.005), reduced lipid arc (-29 ± 12° vs. -18 ± 14°, p = 0.028), and higher % decrease in total lipid arc (-35 ± 13% vs. -19 ± 18%, p = 0.01) as well as a lower MACE incidence (Log rank p = 0.023, HR 4.72 [1.08, 20.63]) and revascularization rate (adjusted HR 6.77 [1.08, 42.52]) compared to the non-SGLT2i group. Conclusions SGLT2i stabilizes atherosclerosis and improves ACS prognosis in patients with T2DM. What is new? We analyzed serial OCT images both baseline and follow-up in patients with ACS and T2DM undergoing PCI, and evaluated how effect SGLT2i had on unstable plaques. ACS patients with SGLT2i administration showed coronary atherosclerotic lesions to be stabilized on follow-up. What are the clinical implications? SGLT2i can stabilize unstable plaques by controlling the inflammatory cascade on patients with T2DM. SGLT2i administration will be one option to improve their prognosis in patients with ACS and T2DM undergoing PCI.
- Open Access
- 2 September 2022
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 38 (2) , 194-201
Five-year clinical outcomes of a 2.25 mm sirolimus-eluting stent in Japanese patients with very small coronary artery disease: final results of the CENTURY JSV study
The aim of this study is to evaluate the long-term safety and efficacy of the 2.25 mm bioresorbable-polymer sirolimus-eluting Ultimaster stent in a Japanese patient population. Treatment of coronary artery disease in very small vessels is associated with an increased risk for cardiac events. The CENTURY JSV study is a prospective, multicenter, single-arm study. Seventy patients with stable and unstable coronary artery disease with a coronary lesion eligible for implantation with a 2.25 mm stent were enrolled in this study. Patients underwent clinical follow-up through 5-year after the PCI procedure. The mean age was 70.4 ± 9.2 years. The prevalence of diabetes mellitus was 37.1%, all not insulin dependent. The incidence of major adverse cardiac events, defined as cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization (CD-TLR) at 5 years was 5.7%. A non-Q wave MI was noted in 1.4% and 4.3% underwent a CD-TLR. There was no stent thrombosis during the entire follow-up period. No cardiac events were reported between 2 and 5 years. This is the first study to demonstrate safety and effectiveness for 5 years after treatment of very small coronary disease with 2.25 mm-diameter DES.Clinical trial registration: UMIN000012928
- 2 September 2022
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 38 (2) , 194-201
Open AccessFive-year clinical outcomes of a 2.25 mm sirolimus-eluting stent in Japanese patients with very small coronary artery disease: final results of the CENTURY JSV study
The aim of this study is to evaluate the long-term safety and efficacy of the 2.25 mm bioresorbable-polymer sirolimus-eluting Ultimaster stent in a Japanese patient population. Treatment of coronary artery disease in very small vessels is associated with an increased risk for cardiac events. The CENTURY JSV study is a prospective, multicenter, single-arm study. Seventy patients with stable and unstable coronary artery disease with a coronary lesion eligible for implantation with a 2.25 mm stent were enrolled in this study. Patients underwent clinical follow-up through 5-year after the PCI procedure. The mean age was 70.4 ± 9.2 years. The prevalence of diabetes mellitus was 37.1%, all not insulin dependent. The incidence of major adverse cardiac events, defined as cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization (CD-TLR) at 5 years was 5.7%. A non-Q wave MI was noted in 1.4% and 4.3% underwent a CD-TLR. There was no stent thrombosis during the entire follow-up period. No cardiac events were reported between 2 and 5 years. This is the first study to demonstrate safety and effectiveness for 5 years after treatment of very small coronary disease with 2.25 mm-diameter DES.Clinical trial registration: UMIN000012928
- 7 October 2020
- Published by Elsevier in Journal of Cardiology
- Vol. 77 (3) , 254-262
Impact of age on mid-term clinical outcomes and left ventricular reverse remodeling after cardiac resynchronization therapy
- 7 October 2020
- Published by Elsevier in Journal of Cardiology
- Vol. 77 (3) , 254-262
Impact of age on mid-term clinical outcomes and left ventricular reverse remodeling after cardiac resynchronization therapy
- Open Access
- 1 August 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (4) , 1-2
Treatment of severe aortic stenosis with scoliosis
An 86-year-old lady complained dyspnoea on effort and came to our hospital. She had severe scoliosis (Panel A). Transthoracic echocardiography demonstrated severe aortic stenosis (mean pressure gradient 59.8 mmHg and aortic valve area 0.63 cm2). Multislice computed tomography revealed calcified tricuspid aortic valve and severe tortuosity in descending aorta with scoliosis (Panel B). The aortic annulus diameter, perimeter, and area were 21.6 mm × 27.4 mm, 77.3 mm, and 468 mm2, respectively. Each sinus of the Valsalva diameter was 33.5 mm in the left coronary cusp, 30.0 mm in the right coronary cusp, and 30.4 mm in the non-coronary cusp. The distance between the annular plane and left coronary artery (LCA) ostium was 8.9 mm, and that between the annular plane and the right coronary artery ostium was 11.0 mm. Preoperative coronary angiography showed LCA dominant coronary arteries and no significant stenosis. Our heart team decided transcatheter aortic valve replacement (TAVR) via transfemoral approach was better treatment because of high age, general frailty, and intermediate risk for surgery (Society of Thoracic Surgeons score: 4.90%). After crossing the calcified aortic valve retrogradely using a straight Radifocus Guidewire (Terumo, Tokyo, Japan), a SAFARI guidewire (Boston Scientific, Marlborough, MA, USA) was placed at a precise position in the mid-left ventricle. Although her descending to ascending aorta was very tortuous due to scoliosis, a balloon-expandable SAPIEN 3 (Edwards Lifescience, CA USA) transcatheter heart valve (THV) could pass through such tortuous vessel via right femoral artery by using commander system with flex catheter (Video 1; Panel C). In addition, the protection of LCA by using guidewires with a balloon was performed due to the low height of LCA from the aortic valve annulus. A 26-mm SAPIEN 3 THV was adjusted carefully, then deployed by nominal volume under rapid pacing. Transcatheter heart valve was implanted successfully in a precise position with minimum paravalvular regurgitation (PVL) by aortography (Panel D). Transthoracic echocardiography after TAVR showed trivial PVL and the mean pressure gradient was less than 7 mmHg. She was discharged 6 days after TAVR without any complication. At follow-up 1 month after TAVR, she was doing well and no cardiac symptoms.
- 1 August 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (4) , 1-2
Open AccessTreatment of severe aortic stenosis with scoliosis
An 86-year-old lady complained dyspnoea on effort and came to our hospital. She had severe scoliosis (Panel A). Transthoracic echocardiography demonstrated severe aortic stenosis (mean pressure gradient 59.8 mmHg and aortic valve area 0.63 cm2). Multislice computed tomography revealed calcified tricuspid aortic valve and severe tortuosity in descending aorta with scoliosis (Panel B). The aortic annulus diameter, perimeter, and area were 21.6 mm × 27.4 mm, 77.3 mm, and 468 mm2, respectively. Each sinus of the Valsalva diameter was 33.5 mm in the left coronary cusp, 30.0 mm in the right coronary cusp, and 30.4 mm in the non-coronary cusp. The distance between the annular plane and left coronary artery (LCA) ostium was 8.9 mm, and that between the annular plane and the right coronary artery ostium was 11.0 mm. Preoperative coronary angiography showed LCA dominant coronary arteries and no significant stenosis. Our heart team decided transcatheter aortic valve replacement (TAVR) via transfemoral approach was better treatment because of high age, general frailty, and intermediate risk for surgery (Society of Thoracic Surgeons score: 4.90%). After crossing the calcified aortic valve retrogradely using a straight Radifocus Guidewire (Terumo, Tokyo, Japan), a SAFARI guidewire (Boston Scientific, Marlborough, MA, USA) was placed at a precise position in the mid-left ventricle. Although her descending to ascending aorta was very tortuous due to scoliosis, a balloon-expandable SAPIEN 3 (Edwards Lifescience, CA USA) transcatheter heart valve (THV) could pass through such tortuous vessel via right femoral artery by using commander system with flex catheter (Video 1; Panel C). In addition, the protection of LCA by using guidewires with a balloon was performed due to the low height of LCA from the aortic valve annulus. A 26-mm SAPIEN 3 THV was adjusted carefully, then deployed by nominal volume under rapid pacing. Transcatheter heart valve was implanted successfully in a precise position with minimum paravalvular regurgitation (PVL) by aortography (Panel D). Transthoracic echocardiography after TAVR showed trivial PVL and the mean pressure gradient was less than 7 mmHg. She was discharged 6 days after TAVR without any complication. At follow-up 1 month after TAVR, she was doing well and no cardiac symptoms.
- 16 April 2020
- Published by Springer Nature in Heart and Vessels
- Vol. 35 (10) , 1323-1330
Impact of bleeding events after percutaneous coronary intervention in patients on hemodialysis
Coronary artery disease is common in patients on dialysis; there is a high rate of bleeding events after percutaneous coronary intervention (PCI) in such patients. We investigated the impact of bleeding events after PCI on mortality in patients on hemodialysis. We included 386 consecutive hemodialysis patients who underwent PCI using a drug-eluting stent (DES) between September 2004 and December 2017 in our hospital, and investigated the impact of bleeding events on all-cause mortality after PCI. Bleeding events were assessed by the Thrombolysis in Myocardial Infarction (TIMI) bleeding definition within 24 months after PCI. A total of 42 patients experienced bleeding events. Of these, 30 patients (71.4%) had TIMI major bleeding events and 12 patients (28.6%) had TIMI minor bleeding events. Patients with bleeding events had significantly higher mortality than patients without bleeding events (survival rate, 55.1% vs 81.5%, log-rank: p < 0.001). These results suggest that bleeding events after PCI with a DES are notably associated with all-cause mortality among patients on hemodialysis. This is the first report about relationship between bleeding events and mortality to focus on patients on hemodialysis.
- 16 April 2020
- Published by Springer Nature in Heart and Vessels
- Vol. 35 (10) , 1323-1330
Impact of bleeding events after percutaneous coronary intervention in patients on hemodialysis
Coronary artery disease is common in patients on dialysis; there is a high rate of bleeding events after percutaneous coronary intervention (PCI) in such patients. We investigated the impact of bleeding events after PCI on mortality in patients on hemodialysis. We included 386 consecutive hemodialysis patients who underwent PCI using a drug-eluting stent (DES) between September 2004 and December 2017 in our hospital, and investigated the impact of bleeding events on all-cause mortality after PCI. Bleeding events were assessed by the Thrombolysis in Myocardial Infarction (TIMI) bleeding definition within 24 months after PCI. A total of 42 patients experienced bleeding events. Of these, 30 patients (71.4%) had TIMI major bleeding events and 12 patients (28.6%) had TIMI minor bleeding events. Patients with bleeding events had significantly higher mortality than patients without bleeding events (survival rate, 55.1% vs 81.5%, log-rank: p < 0.001). These results suggest that bleeding events after PCI with a DES are notably associated with all-cause mortality among patients on hemodialysis. This is the first report about relationship between bleeding events and mortality to focus on patients on hemodialysis.
- 25 February 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (1) , 20-28
The efficacy of modified jailed balloon technique for true bifurcation lesions
Objective: To evaluate the short‐, long‐term clinical and angiographic outcomes after treatment of true bifurcation lesions using a modified jailed balloon technique (MJBT).Background: Percutaneous coronary intervention (PCI) for true bifurcation lesions has high risk for adverse events. Side branch (SB) occlusion is one of the most serious complications. Therefore, novel strategies to avoid SB occlusion during main branch stenting and to keep its patency are important.Methods and Results: Between February 2015 and February 2018, 328 patients with 349 true bifurcation lesions underwent PCI using MJBT. True bifurcation lesions were defined as Medina classifications (1.1.1), (1.0.1) or (0.1.1) lesions. We investigated the procedural and long‐term clinical outcomes. Furthermore, angiographic outcomes were assessed at follow‐up diagnostic angiography.The mean age of patients was 71.6 ± 9.9 years. Procedural success was achieved in all patients; postoperative SB occlusion was noted in only one patient (0.3%). The cumulative incidence of all‐cause death was 23 patients (7.0%) in the follow‐up period (median 717 days). Target lesion revascularization was performed in 19 patients (5.8%) with 23 lesions (6.6%), and 0.6% of myocardial infarction and 0% of definite stent thrombosis were observed. Angiographic follow‐up was performed in 243 patients (74.1%); the percent diameter stenosis in SB was not significantly different between after the index procedure and follow‐up angiography.Conclusions: This MJBT is safe and effective in preserving SB patency for true bifurcation lesions. Furthermore, long‐term clinical and angiographic outcomes after MJBT are feasible.
- 25 February 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (1) , 20-28
The efficacy of modified jailed balloon technique for true bifurcation lesions
Objective: To evaluate the short‐, long‐term clinical and angiographic outcomes after treatment of true bifurcation lesions using a modified jailed balloon technique (MJBT).Background: Percutaneous coronary intervention (PCI) for true bifurcation lesions has high risk for adverse events. Side branch (SB) occlusion is one of the most serious complications. Therefore, novel strategies to avoid SB occlusion during main branch stenting and to keep its patency are important.Methods and Results: Between February 2015 and February 2018, 328 patients with 349 true bifurcation lesions underwent PCI using MJBT. True bifurcation lesions were defined as Medina classifications (1.1.1), (1.0.1) or (0.1.1) lesions. We investigated the procedural and long‐term clinical outcomes. Furthermore, angiographic outcomes were assessed at follow‐up diagnostic angiography.The mean age of patients was 71.6 ± 9.9 years. Procedural success was achieved in all patients; postoperative SB occlusion was noted in only one patient (0.3%). The cumulative incidence of all‐cause death was 23 patients (7.0%) in the follow‐up period (median 717 days). Target lesion revascularization was performed in 19 patients (5.8%) with 23 lesions (6.6%), and 0.6% of myocardial infarction and 0% of definite stent thrombosis were observed. Angiographic follow‐up was performed in 243 patients (74.1%); the percent diameter stenosis in SB was not significantly different between after the index procedure and follow‐up angiography.Conclusions: This MJBT is safe and effective in preserving SB patency for true bifurcation lesions. Furthermore, long‐term clinical and angiographic outcomes after MJBT are feasible.